522629-15-8

Basic information

• Product Name: Benzenepropanenitrile, 4-fluoro-beta-hydroxy-, (betaR)- (9CI)
• Synonyms: Benzenepropanenitrile, 4-fluoro-beta-hydroxy-, (betaR)- (9CI)
• CAS NO: 522629-15-8
• Molecular Formula: C9H8FNO
• Molecular Weight: 165.1643232
• Product Categories: HALIDE
• Mol File: 522629-15-8.mol
• Article Data: 34

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenepropanenitrile, 4-fluoro-beta-hydroxy-, (betaR)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenepropanenitrile, 4-fluoro-beta-hydroxy-, (betaR)- (9CI)(522629-15-8)
• EPA Substance Registry System: Benzenepropanenitrile, 4-fluoro-beta-hydroxy-, (betaR)- (9CI)(522629-15-8)

Safety Data

• Hazardous Substances Data: 522629-15-8(Hazardous Substances Data)

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 75-05-8 acetonitrile 
• 4640-67-9 3-(4-fluorophenyl)-3-oxopropionitrile 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 403-43-0 4-fluorobenzoyl chloride 
• 136568-65-5 (RS)-3-(4-fluorophenyl)-3-hydroxypropionitrile 
• 590-17-0 cyanomethyl bromide 
• 18293-53-3 2-trimethylsilylacetonitrile 
• 403-29-2 2-bromo-4'-fluoroacetophenone 
• 624-75-9 iodoacetonitrile 
• 111873-50-8 dibutyl(cyanomethyl)telluronium chloride 
• 773837-37-9 sodium cyanide 
• 18511-62-1 4-fluorostyrene oxide 

Downstream Products

• 1374417-22-7 C₁₂H₁₁FO 

Relevant articles and documents

Continuous-flow stereoselective reduction of prochiral ketones in a whole cell bioreactor with natural deep eutectic solvents

Immobilized whole cells of Rhodotorula rubra MIM147 were used in a packed bed flow reactor for the enantioselective reduction of β-ketonitriles and for the efficient production of a key building block for the synthesis of the antidepressant drug duloxetin

Novel Thienopyrimidones

This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.

Synthesis of β-hydroxyamides through ruthenium-catalyzed hydration/transfer hydrogenation of β-ketonitriles in water: Scope and limitations

A cascade process for the straightforward one-pot conversion of β-ketonitriles into β-hydroxyamides is presented. The process, that proceeds in water employing the arene-ruthenium(II) complex [RuCl2(η6-p-cymene){P(4-C6H4F)2Cl}] as catalyst in combination with sodium formate, involves the initial hydration of the β-ketonitrile substrates to generate the corresponding β-ketoamide intermediates, which subsequently undergo the transfer hydrogenation (TH) of the carbonyl group. Employing a family of forty different β-ketonitriles, featuring diverse substitution patterns, the scope and limitations of the process have been established.